A history of maternal asthma remains among the most robust predictors of virus-induced lower respiratory tract infections in infancy, and childhood-onset asthma with an odds ratio (OR) of 3.0 (95% CI, 2.6-3.6) for asthma in a pooled analysis of 33 studies.
1 Surprisingly, the impact of asthma control, exacerbations, and asthma management during pregnancy on the offspring's asthma risk remains poorly studied. However, an increased risk for asthma has been reported in a retrospective case-control study of children whose mothers had moderate-tosevere uncontrolled asthma during pregnancy. 2 Asthma during pregnancy may shape the child's future asthma risk trajectory via an interaction between heritability and in utero exposures at the feto-maternal interface. Notably very common exposures such as asthma medications and exacerbations during pregnancy have not been investigated for an association with the child's asthma risk.
The Managing Asthma in Pregnancy (MAP) study was a double-blind randomized controlled trial (RCT) in asthmatic women. 3 It compared the efficacy of a management algorithm that combined the noninvasive assessment of T H 2 cell cytokine (IL-4 and IL-13)-induced airways inflammation by means of measuring the fractional exhaled nitric oxide (FENO) and asthma symptoms (FENO group) against a symptoms-only approach (clinical group). Total asthma exacerbations were reduced (incidence rate ratio, 0.50; 95% CI, 0.33-0.76) in the FENO group, compared with the clinical group. 3 At the end of the study, more pregnant women took inhaled corticosteroids (ICS) and ICS plus long-acting b-agonists-but in a lower mean ICS dose-in the FENO group as a result of the treatment algorithm (68.5% vs 42.2%, P < .0001 and 40.5% vs 17.4%, P < .0001). In contrast, fewer women in the FENO group as compared to the clinical group needed short-acting b-agonist treatment in the last RCT week (median [interquartile range (IQR), 0 [0-3] days vs 1 [0-5] days; P 5 .024). There were no differences in FENO levels, FEV 1 , and FEV 1 % between the groups. 3 During the MAP RCT, mothers were invited to have their offspring participate in the Growing into Asthma (GIA) birth cohort study. At 12 months of age, we conducted the first follow-up visit to investigate the parent-reported incidence of virus-induced wheezy lower respiratory tract infections (''bronchiolitis''). We found that infants born to mothers from the FENO group had a reduced risk for recurrent bronchiolitis episodes in the first year of life (OR, 0.08; 95% CI, 0.01-0.66). 4 Notably, the Childhood Origins of Asthma (COAST) birth cohort of high-risk children born to parents with asthma or allergy reported an association between moderate-to-severe wheezy illnesses in the first 3 years of life and asthma by age 6 years. ORs ranged between 2.6 (95% CI, 1.0-6.3) for respiratory syncytial virus-induced and 9.8 (95% CI, 4.3-22.0) for rhinovirus-induced wheezing illnesses. 5 Furthermore, a single nucleotide polymorphism at a highly replicated asthma locus on chromosome 17q21 (rs7216389) 6 was associated with a genotype-specific risk for asthma only in children with a rhinovirus-induced wheezing illness in early life (P 5.004).
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The ORM (yeast)-like protein isoform 3 (ORMDL3) protein, coded at the 17q21 locus, has been shown to be associated with a cellular stress response and release of proinflammatory molecules involved in airways remodelling and inflammation. [8] [9] [10] The results from the COAST study in conjunction with our findings provided a strong rationale to prospectively test the hypothesis in the GIA cohort proposed earlier 4 that ''asthma in pregnancy is a potentially modifiable determinant in the prenatal origins of bronchiolitis with the prospect to be evaluated as a potential primary preventative strategy that could modulate the risk of childhood asthma.'' The primary aim of the GIA study was to determine the effect of FENO-guided asthma management during pregnancy on asthma incidence in childhood, and the secondary aim was to determine asthma-related symptoms and health care utilization. In further explorative analyses, we aimed to investigate the role of ICS in mediating and the relevance of 17q21 variants in modifying the effect of FENO-guided asthma management on childhood asthma.
METHODS

Study design and participants
The GIA study is a prospective, longitudinal, observational birth cohort study following the offspring of women with asthma during pregnancy who participated in the MAP study, a double-blind RCT conducted in Newcastle, Australia (Australian New Zealand Clinical Trials Registry, no. 12607000561482). 3 Children included were born from February 6, 2008 , to November 25, 2010 ; 174 mothers with 179 children (1 set of triplets and 3 sets of twins) were subsequently recruited to the GIA study, of whom 146 were assessed at 12 months (82% participation) 4 and 140 (78%) at 4 to 6 years of age (see Fig E1 in this article's Online Repository at www.jacionline.org). The predefined primary aim 4 of the follow-up at 4 to 6 years of age was to determine the effect of FENO-guided asthma management during pregnancy on the incidence of childhood asthma. The mothers, children, and all study personnel involved in the follow-up visits and collection of biosamples were blinded as to which treatment group the mother was allocated during pregnancy. The study was approved by the Hunter New England Health and University of Newcastle Human Research Ethics Committees (ref 12/06/20/4.03), and written informed consent was obtained before inclusion in the study.
Procedures and outcomes in the MAP study
The primary aim of the MAP study was to test the efficacy of a treatment algorithm using monthly FENO measurements in combination with asthma symptoms (defined by Asthma Control Questionnaire, 11, 12 FENO group) against a symptoms-only approach (clinical group) for the adjustment of maintenance therapy with ICS with and without long-acting b-agonists in pregnant women with asthma. Eligible women were randomized before 22 weeks' gestation, and those with uncontrolled asthma who were not using ICS as maintenance treatment (n 5 31) were started on budesonide (200 mg twice per day) before randomization. Women using ICS continued with their current dose, delivered as budesonide turbuhaler (AstraZeneca, North Ryde, New South Wales, Australia), with dose equivalence determined from guidelines. Women were reviewed monthly at the antenatal clinic until delivery. The research assistant collected data for the clinical symptoms, Asthma Control Questionnaire score, current treatments, FENO, and FEV 1 in both groups. A statistician applied the relevant algorithm and sent the treatment recommendation to the research assistant in the antenatal clinic, who informed the participant. Participants were seen by an investigator (P.G.) in the antenatal clinic if their asthma remained uncontrolled despite being at maximum treatment level in the algorithm. Telephone assessments were done 2 weeks after each clinic visit to assess symptoms and to encourage drug adherence. Maternal asthma exacerbations during pregnancy were defined as events for which the patient sought medical attention (an unscheduled visit to a doctor, presentation to the emergency department, admission to hospital, or when oral corticosteroids were used for treatment of asthma). All exacerbations that occurred after randomization were recorded prospectively.
Procedures and outcomes in the GIA study Questionnaires completed by the parent/carer were the International Study of Asthma and Allergies in Childhood core questionnaire (wheezing, rhinitis, and eczema modules for 6-to 7-year-old children) 13 and additional standardized respiratory symptom questions validated for preschoolers. 14, 15 A clinical examination of the child and standardized interview of the primary carer was conducted by a senior medical doctor (advanced trainee level in pediatrics or greater), to confirm the appropriateness of a doctor diagnosis of asthma in accordance with national asthma guidelines. 16 Buccal swabs were collected for DNA extraction and atopy was defined as a positive response (> _3 mm wheal) to any of the common aeroallergens Dermatophagoides pteronyssinus, Dermatophagoides farinae, cat, dog, Aspergillus fumigatus, 5 grass mix, and the standard food allergens-whole peanut extract, egg yolk, and egg white. Blood sample collection was offered as an opt-in investigation.
Lung function measurement was attempted in all willing participants during attendance at the preschool age checkup. Multiple breath nitrogen washout was performed using Exhalyzer D (EcoMedics, Duernten, Switzerland) in accordance with the consensus statement for inert gas washout measurements using multiple-and single-breath washout 17 and was successfully measured (> _2 measurements with a coefficient of variance within 10%) in 96 of 128 children (75%) who were willing to be tested. Impulse oscillometry was conducted using a combined commercial system (MasterScreen system, Jaeger, Wuerzberg, Germany) and was successful in 104 of 122 children (85%). Successful measurement was classified as > _3 measurements (coefficient of variance within 10%) with a best coherence threshold > _0.6 at 5 Hz and > _0.9 at 20 Hz. Single breath FENO was also performed according to American Thoracic Society/European Respiratory Society recommendations 18 in order to familiarize the child with the test procedure for future follow-up visits, even though the expiratory maneuver can be challenging at preschool age. We used the CLD88 instrument (EcoMedics) and acceptable measurements (> _2 measurements with a coefficient of variance within 5% or 3 measurements within 10%) were recorded in 50 of 125 children (40%).
DNA extraction and genotyping of 17q21 variants
DNA was successfully extracted from 139 of the 140 buccal swabs from participating children collected at a follow-up visit (either preschool or 12-month visit) using the Gentra Puregene Buccal Cell kit (Qiagen, Hilden, Germany). DNA concentration and quality were measured using a Nanodrop ND-1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, Mass).
Five previously reported childhood onset asthma-associated single nucleotide polymorphisms at locus 17q21 were genotyped (rs8069176, rs7216389, rs8076131, rs9303277, rs2290400). Genotyping was performed using the TaqMan (Applied Biosystems, Thermo Fisher Scientific) assays and previously described primers and probes. 7, 19 Genotyping success rates were 100% for all variants.
RNA extraction from PBMCs and measurement of ORMDL3 gene expression
Five milliliters of whole blood was collected from 72 consenting children (51%). PBMCs were isolated from whole blood samples using the Lymphoprep separation protocol (STEMCELL Technologies, Vancouver, British Columbia, Canada). After PBMC isolation, cells were counted on a hemocytometer and resuspended in 10% FCS RPMI at 1 3 10 6 cells/mL. Cells were plated into 96-well round-bottom plates at 2 3 10 5 /well and incubated at 37 8 C for 5 days. Total mRNA was extracted using TRIzol (Ambion, Thermo Fisher Scientific). All steps were performed according to manufacturer's instructions.
ORMDL3 and hypoxanthine-guanine phosphoribosyltransferace primers (see Table E1 in this article's Online Repository at www.jacionline.org) were obtained from Jomar Biosciences (Scoresby, Victoria, Australia) and quantitative PCR was run using SYBR green (Qiagen). ORMDL3 was successfully amplified in 71 of 72 PBMC samples. Each quantitative PCR reaction was run in duplicate and only duplicates with a coefficient of variance of <0.05 were included in the analysis. We quantified mRNA copies using cDNA standards for all genes. We normalized expression levels to the house-keeping gene HPRT.
Statistical analysis
Categorical measures were summarized using counts and percentages while continuous measures were summarized using means and SDs or SEMs for normally distributed data, or alternatively medians and IQRs. Data were analyzed according to the treatment intervention group to which the mothers were randomized. Due to the very low amount of missing data, we present a complete case analysis under the missing completely at random assumption. Statistical significance for continuous secondary outcome variables was determined using a nonparametric, 2-tailed Mann-Whitney U test or the parametric Student t test as appropriate. Categorical variables were compared using chi-squared or Fisher exact test as appropriate. Estimates of the effect size of the pregnancy intervention on childhood asthma risk (primary outcome) were calculated as unadjusted ORs and obtained using logistic regression models. We also adjusted the models for sex, birth weight, rs8076131, rs8069176, rs9303277, rs7216389, rs2290400, and inhaled corticosteroid use prior to the first RCT screening visit. In further explorative analyses, the estimates of the effect size of medications (ICS or long-acting b-agonists at screening visit, randomization, and last visit) on childhood asthma risk were also calculated as ORs and obtained using logistic regression models. These models were adjusted for sex, birth weight, rs8076131, rs8069176, rs9303277, rs7216389, and rs2290400. In order to investigate for interaction between 17q21 variants and intervention, interaction terms were included in the logistic regression analysis along with confounders. Predictor variables were tested for collinearity using variance inflation factors post estimation. The cutoff for statistical significance was set at 5% for all analyses.
A causal mediation analysis (parametric regression approach described by VanderWeele 20, 21 ) was used to decompose the effect of the FENO intervention versus ICS use during pregnancy on childhood asthma. We considered ''ICS use at any visit during the study'' as a mediator (with a logistic regression model), as well as ''time to first change in ICS dose'' (imperfectly modelled as a linear regression since there are no methods capable of dealing with a censored time-to-event mediator variable). Smoking status was accounted for as a confounder of the mediator outcome relationship under the assumption that there are no unmeasured confounders of this relationship. We present the Data shown as n/n (%), medians (25th, 75th), or means 6 SEMs for normally distributed datasets unless otherwise indicated. A, Adenine; C, cytosine; G, guanine; T, thymine.
natural indirect effect (on the OR scale), representing the effect that a treatment-induced change in mediator has on asthma. SEs and CIs for the indirect effects were obtained via nonparametric bootstrapping (with n 5 500 replicates sampled with replacement); lower and upper bounds of the interval are presented as the 2.5th and 97.5th percentiles of the bootstrapped distribution. To complete the mediation analysis, we also assessed the associations of each path separately. The association between treatment group and any use of ICS was assessed using logistic regression; the association between treatment group and time from baseline to first change in ICS dose was assessed using discrete time survival analysis. The association between any ICS use (or time to first change in ICS dosage) and asthma was assessed using logistic regression. A Kaplan-Meier plot for the differences between treatment groups in time to first ICS dosage change is also provided. Hazard ratios (or ORs) with 95% CIs are presented. All analyses were programmed in Stata 13 (StataCorp, College Station, Tex) and plots were produced using Prism Graph 6 (GraphPad Software, La Jolla, Calif).
RESULTS
Subject characteristics; prenatal and perinatal history
There were 140 children (78%) who attended the follow-up visit between the ages of 4 and 6 years (mean age, 59 months) ( Table I ). The intervention groups were balanced regarding the child's sex, age, height and weight, allergic sensitization, and five 17q21 variants (Table I) .
Childhood asthma, respiratory symptoms, and asthma management during pregnancy Prevalence of doctor-diagnosed asthma was 36% (50 of 139) in this high-risk cohort. A significantly lower rate of asthma was observed in the offspring of mothers from the FENO group, compared with the clinical management group (unadjusted OR, 0.46; 95% CI, 0.22 to 0.96; P 5 .037) ( Table II) . The prevalences for wheeze ever, use of short-acting b-agonists in the past 12 months, emergency department visits for wheezing or asthma in the last 12 months, and frequent wheeze past 12 months were also significantly lower in the FENO group (Table II) . Significantly fewer children from the FENO group had a past history of recurrent episodes of bronchiolitis at preschool age (Table II) .
Risk factors of childhood asthma
Children diagnosed with asthma were less likely to be female and more likely to have a past history of bronchiolitis and a lower birth weight (Table III) . Maternal ICS use at the screening, randomization, and final study visit reduced the OR for childhood asthma (OR, 0.24, 0.35, and 0.46; P 5 .002, .005, and .032, respectively) (Table III) . Average maternal FENO levels during the RCT and FENO levels at the final study visit were not significantly associated with childhood asthma (Table III) . Doctor-diagnosed asthma was significantly associated with risk alleles in the 17q21 variants rs8069176 and rs8076131 (OR, 1.98 and 1.80; P 5 .013 and .033, respectively) (Table III) , as well as increased airway resistance at 5 Hz and FENO levels but not baseline FEV 1 and lung clearance index in the children (see Table E2 in this article's Online Repository at www.jacionline.org).
Childhood asthma, asthma management, and ICS use during pregnancy
In further explorative analyses, we stratified the cohort into 4 groups of children based on the maternal asthma management group (FENO or clinical) and the use of ICS (yes or no) at the RCT randomization and final RCT visit (Table IV) . The highest prevalence of asthma was observed in those children whose mothers were in the clinical group and did not use ICS at randomization or final study visit (reference group). The ORs for doctor-diagnosed asthma (Fig 1 and Table IV ), wheeze ever, and short-acting bronchodilator use in past 12 months (Table IV) were significantly lower in children whose mothers were in the FENO group and whose mothers were in the clinical group and using ICS.
A causal mediation analysis was performed to determine to what extent the FENO intervention caused a reduction in childhood asthma via ''ICS use at any visit during the study'' (natural indirect effect). This analysis confirmed a significant natural indirect effect of the FENO intervention on asthma prevalence through ''ICS use at any visit during the study'' (OR, 0.83; 95% CI, 0.59-0.99). This amounts to approximately 30% of the total effect of FENO intervention while the remainder was through other pathways. We hypothesized that the FENO intervention may also have affected the time to the first change in ICS dose. This P values and ORs were calculated using unadjusted and adjusted logistic regression models. *Adjusted for sex, birth weight, rs8076131, rs8069176, rs9303277, rs7216389, rs2290400, and first visit ICS use.
hypothesis was consistent with Kaplan-Meier estimates of survival probabilities for ''time to first change in ICS dose'' that showed that the clinical group had a significantly longer time to first change in ICS dose compared with the FENO group (hazard ratio, 1.87; 95% CI, 1.22-2.84; P 5.004) (Fig 2) . The natural indirect effect of FENO intervention on childhood asthma through decreasing time to first ICS dosage change also appeared important in a subsequent causal mediation analysis (OR, 0.90; 95% CI, 0.70-1.03). The natural indirect effects of FENO intervention through ''ICS use at any visit during the study'' and ''time to first change in ICS dose'' are consistent with Fig 1: among children who were born to women that did not use ICS the absolute difference between intervention groups in asthma prevalence was greater; among children who were born to women that did use ICS the absolute difference between intervention groups in asthma prevalence was smaller.
Childhood asthma, 17q21 variants, and maternal asthma management during pregnancy Asthma risk was significantly increased by risk alleles in all 5 17q21 variants among those children (n 5 90) with a prior history of bronchiolitis in accordance with previous reports 7, 22 (Fig 3 for  rs7216389 and see Table E3 in this article's Online Repository at www.jacionline.org). As expected, none of the 17q21 risk alleles were associated with asthma in those children who never had bronchiolitis (n 5 78). These gene-environment interactions between bronchiolitis and risk alleles were significant for 3 of the 5 17q21 variants. We also found a significant association between risk alleles in 3 of 5 17q21 variants (rs2290400, rs9303277, rs7216389) and the expression patterns of ORMDL3 in PBMCs collected in our cohort (Fig 3 for rs7216389) . Although bronchiolitis was a risk factor for childhood asthma (Table III) and recurrent bronchiolitis episodes were reduced in children from the FENO group (Table II) , we could not identify any significant interaction between any risk allele in the 5 17q21 variants and the asthma management intervention during pregnancy (Fig 3 for rs7216389, Table E3 ).
DISCUSSION
The results of our study have demonstrated for the first time that FENO-guided asthma management during pregnancy reduced the odds for doctor-diagnosed asthma in preschool children. This Data shown as n/n (%), medians (25th, 75th), or means 6 SEMs for normally distributed datasets unless otherwise indicated. P values and ORs were calculated using unadjusted logistic regression models.
LABA, Long-acting b-agonist; ppb, parts per billion.
intervention was also associated with a significantly reduced risk of frequent wheeze and recurrent bronchiolitis, and less medication use and emergency department visits for wheeze and asthma in the past 12 months prior to the follow-up assessment.
A strength of our study is the randomized, controlled design of the MAP study's asthma management intervention along with comprehensive prospective data collection on asthma exacerbations, medications, and FENO levels throughout pregnancy. Furthermore, our previously published studies on FENO-guided asthma management in pregnancy and bronchiolitis risks in infancy provided a strong scientific rationale for the primary hypothesis to be tested in the GIA study. 4 We acknowledge that a diagnosis of childhood asthma is considered more uncertain the younger the child is. However we demonstrated that childhood asthma diagnosed by the study doctor who was blinded to the mother's pregnancy intervention was associated with common asthma risk factors and asthma-like symptoms, as well as with genetic variants at the 17q21 locus, increased airways resistance at 5 Hz, and elevated FENO levels in our preschool cohort. We also confirmed previously described gene-environment interactions at the 17q21 locus 7, 22 in an Australian cohort. Finally we provided functional evidence of variants at locus 17q21 resulting in differences in ORMDL3 expression in a child cohort. This allowed us to demonstrate that FENO-guided asthma management reduced the odds for childhood asthma independent of risk alleles for early onset asthma at the 17q21 locus. We found no evidence for a statistical interaction between 17q21 variants in the offspring and FENO-guided management for the risk of asthma. It is possible, however, that a yet to be determined maternal genotype may interact with FENO-guided management to modify asthma risk. Bisgaard et al 23 observed that supplementation of fish oil-derived fatty acids in pregnancy had a greater effect on wheeze and asthma development in children of mothers with a variant in the gene encoding fatty acid desaturase that was associated with lower blood levels of long-chain polyunsaturated fatty acids.
A major effect of FENO-guided asthma management during pregnancy was a reduction in asthma exacerbations during pregnancy; however, this was not associated with childhood asthma risk (Table III) . We reported previously 3 that FENO-guided asthma management also resulted in an increase in ICS and ICS/long-acting b-agonists use during pregnancy. Therefore it was not unexpected to find a decrease in childhood asthma risk if the mother used ICS (Table III) . However, we also found that ICS use at the RCT screening visit, which represents pregnancy exposure prior to any intervention, showed a strong inverse relationship with childhood asthma prevalence (OR, 0.24; 95% CI, 0.10-0.59; P 5 .002). This raised the possibility that some of the benefit of the FENO intervention on childhood asthma may have been mediated by more appropriate ICS use during pregnancy, which was supported by a causal mediation analysis. We also found that time to first change in ICS dose was significantly reduced in the FENO group compared with the control group (Fig 3) . Time to first change in ICS was probably also an important effect mediator, further highlighting the complex effects that FENO-guided asthma management algorithm had on the use of ICS in pregnancy.
Furthermore, ICS use at the final RCT visit was associated with a lower asthma risk in the clinical group (Fig 1) . This suggests that there may be a potential beneficial effect of ICS therapy in pregnancy for reducing childhood asthma risk. We propose that FENO-guided asthma management resulted in an optimized monthly treatment decision regarding the use and dose of ICS by considering T H 2 cytokine-induced airway inflammation along with clinical symptoms. Importantly, our results provide long-term child health outcomes to further support the clinical consensus that the benefits of ICS therapy in pregnancy, when Data shown as n/n (%) and ORs (95% CIs). P values and ORs were calculated using adjusted logistic regression models. ORs (95% CIs) are adjusted for sex, birth weight, rs8076131, rs8069176, rs9303277, rs7216389, and rs2290400.
guided by FENO levels and clinical symptoms, largely outweigh their potential risks. FENO-guided management and ICS maintenance treatment may have resulted in reduced T H 2 inflammation during pregnancy and led to changes at the feto-maternal interface that suppressed the development of asthma in early childhood. We previously showed that asthma during pregnancy resulted in differential methylation profiles in the infant's blood DNA. 24 Epigenetic changes may have affected airway growth, lung repair and regeneration, or the child's immune response. Interestingly, we found no effect of the pregnancy intervention on atopy, suggesting changes that are independent of the child's IgE-mediated immune response.
Our study has limitations. First, despite good participation, our cohort is small; however, the effect size is large and significant in this high-risk cohort. Our results will enable the design of future appropriately powered RCTs for other outcomes, for instance the proportion of children with bronchodilator reversibility in respiratory resistance at 5 Hz between the intervention groups. In this regard, we are currently conducting the multicenter Breathing for Life RCT (Australian New Zealand Clinical Trials Registry, no. 12613000202763) to test the effect of FENO-guided asthma management on perinatal outcomes (primary outcome) and have begun a stage 2 pediatric follow-up study to determine prespecified childhood outcomes informed by the GIA study. 25 A study doctor who took into account parent-reported symptoms made the diagnosis of asthma. This can be inaccurate in preschool aged children although it should have affected both groups equally as mothers and staff remain blinded. In accordance, we found no difference in the association between 17q21 variants and childhood asthma in children from the clinical and FENO group. Fewer children from the FENO group participated in the follow-up visit. Investigating the reasons for nonparticipating at the preschool follow-up visit revealed that more children from the FENO versus clinical group moved out of the area (14 vs 5 children, respectively) and more did not attend the visit despite scheduling appointments 3 times (6 vs 2 children) (Fig E1) . We have conducted phone interviews with the parents of children who were unable to attend the follow-up visit but consented to provide information by phone. We could get in contact with 15 parents after attempting on > _3 separate occasions. The interviewer and parent remained fully blinded regarding treatment group allocation. The prevalence for doctordiagnosed asthma in the clinical group was 40% (2 of 5) and in the FENO group, it was 30% (3 of 10). When reanalyzing the results with all children included, we confirmed a significantly lower rate of doctor-diagnosed asthma in the offspring of mothers from the FENO group, compared with the clinical management group (unadjusted OR, 0.497; 95% CI, 0.229-0.989; P 5 .047; n 5 154). These data further help to ensure that there is no attrition bias.
We have demonstrated that management of asthma during pregnancy with a FENO-guided strategy, which adjusted treatment according to both symptoms and airway inflammation, reduced the odds of asthma at the age of 4 to 6 years of age by >50%. Implementation of this approach in clinical practice has the potential to reduce asthma rates among a group of children at high risk of developing the disease. 
